

TESTOSTERONE TOPICAL PRIOR APPROVAL REQUEST

Send completed form to: Service Benefit Plan Prior Approval P.O. Box 52080 MC 139 Phoenix, AZ 85072-2080 Attn. Clinical Services Fax: 1-877-378-4727

Federal Employee Program. **PRIOR APPROVAL REQUEST** Additional information is required to process your claim for prescription drugs. Please complete the patient portion, and have the prescribing physician complete the physician portion and submit this completed form.

Patient Information (required)			Provider Information (required)			
Date:			Provider Name:			
Patient Name:			Specialty:		NPI:	
Date of Birth:	Sex: DMale DFemale		Office Phone:		Office Fax:	
Street Address:			Office Street Address:			
City:	State:	Zip:	City:	Sta	ate:	Zip:
Patient ID: R			Physician Signature:			
DIVELCIAN COMDI ETES						

PHYSICIAN COMPLETES

Testosterone Topical

NOTE: Form must be completed in its entirety for processing

Please select topical product, strength(s), and provide quantity being requested for 90 days:

Androderm patch			Fortesta pump		
□2mg	quantity	every 90 days	□120 pump/60gm	quantity	_ every 90 days
□4mg	quantity	every 90 days			
AndroGel 1% packet/pump		Testim tube	quantity	_ every 90 days	
□2.5gm	quantity	_ every 90 days			
□5gm	quantity	_ every 90 days			
□Pump	quantity	_ every 90 days			
AndroGel 1.62% packet/pump		Vogelxo bottle/packet/tube			
□1.25gm	quantity	_ every 90 days	1% (1.25mg) bottle	quantity	_ every 90 days
□2.5gm	quantity	_ every 90 days	1% (50mg) packet	quantity	_ every 90 days
□Pump	quantity	_ every 90 days	1% (50mg) tube	quantity	_ every 90 days
Axiron 30mg/1.5mL solution					
□60 pumps per 90ml	quantity	overy 00 dove			
abo pumps per 90m		_ every 90 days			

**Check www.fepblue.org/formulary to confirm which medication is part of the patient's benefit

Is this request for brand or generic? DBrand DGeneric

- 1. Will this medication be used in combination with any other form of testosterone? □Yes* □No **If YES*, please specify the medication: ______
- 2. Is the patient being treated for gender dysphoria (GD), gender identity disorder (GID), sex transformation, or sex change? *Answer below:* □**YES**: Is the patient undergoing a female to male transition? □**Yes** □No

DNO: Please answer the following questions:

- a. Is the patient assigned female or male at birth? Male Female
- b. What is the patient's diagnosis?

Deficiency of testosterone Androgen deficiency Hypogonadism Low testosterone (Low T)

Testicular hypofunction

Other	(please	specify):	_
-------	---------	-----------	---

PLEASE PROCEED TO <u>PAGE 2</u> FOR DEFICIENCY OF TESTOSTERONE, ANDROGEN DEFICIENCY, HYPOGONDADISM, LOW T, OR TESTICULAR HYPOFUNCTION DIAGNOSIS

PAGE 1 of 2

The information provided on this form will be used to determine the provision of healthcare benefits under a U.S. federal government program, and any falsification of records may subject the provider to prosecution, either civilly or criminally, under the False Claim Acts, the False Statements Act, the mail or wire fraud statutes, or other federal or state laws prohibiting such falsification. **Prescriber Certification:** I certify all information provided on this form to be true and correct to the best of my knowledge and belief. I understand that the insurer may request a medical record if the information provided herein is not sufficient to make a benefit determination or requires clarification and I agree to provide any such information to the insurer. Testosterone Topical – FEP MD Fax Form Revised 4/18/2025



TESTOSTERONE TOPICAL

Federal Employee Program. PRIOR APPROVAL REQUEST

Send completed form to: Service Benefit Plan Prior Approval P.O. Box 52080 MC 139 Phoenix, AZ 85072-2080 Attn. Clinical Services Fax: 1-877-378-4727

Additional information is required to process your claim for prescription drugs. Please complete the patient portion, and have the prescribing physician complete the physician portion and submit this completed form.

PAGE 2 - PHYSICIAN COMPLETES				
Patient Name:	DOB:	Patient ID: R		
	patient been on testosterone therapy in any excluding samples? <i>Please select the answer b</i>	dosage form (Injection, topical, oral, etc.) continuously for the last 4 <i>elow:</i>		
\Box NO –	this is INITIATION of testosterone therapy	, please answer the following questions:		
i. Has	s the patient had two morning total testoster	one levels less than 300 ng/dL on different days? \Box Yes \Box No		
ii. W	'hat is the patient's hematocrit?	% Hematocrit was not tested		
iii. D	Does the patient have a current diagnosis of p	rostate cancer? Types INo		
iv. D	oes the patient have palpable prostate nodul	es? \Box Yes \Box No		
	I I I I I I I I I I I I I I I I I I I	□No* te specific antigen (PSA) which is less than 4 ng/ml? <i>Answer below:</i>		
	boes the patient have a concurrent diagnosis of <i>if YES</i> , will the patient be monitored for w	of benign prostatic hyperplasia (BPH)? □Yes* □No orsening symptoms of BPH? □Yes □No		
	Does the patient have a diagnosis of sleep ap * <i>If YES</i> , is the patient being treated for their			
	Has the prescriber assessed the patient for stroke? □Yes □No	their cardiovascular risk for myocardial infarction (MI), angina, or		
	- this is a PA renewal for CONTINUATIO bes the patient have a total testosterone level	N of therapy, please answer the following questions: 800 ng/dL or less? □Yes □No		
ii. Ha	as the patient had a prostatectomy? □Yes	□No		
		of benign prostatic hyperplasia (BPH)? □Yes □No BPH worsened since beginning testosterone therapy? □Yes □No		
iv. W	Vill the patient's prostate specific antigen (PS	SA) level be tested every 12 months? \Box Yes \Box No		
v. Wi	ill the patient's serum testosterone concentration	tions be monitored every 12 months? \Box Yes \Box No		
	Vill the patient's hematocrit levels be monito	•		
vii. H	1	r their cardiovascular risk for myocardial infarction (MI), angina, or		